{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:58:51Z","timestamp":1785265131832,"version":"3.55.0"},"reference-count":31,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"unspecified","delay-in-days":104,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,3,5]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      The multinational ERYTHRO (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06046534\">NCT06046534<\/jats:ext-link>\n                      ) study investigated the experience of patients with moderate-to-severe SLE initiating anifrolumab treatment through routine clinical practice as part of two early access programmes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Retrospective data were extracted from medical charts of adults with SLE who received intravenous anifrolumab 300\u2009mg every 4 weeks alongside standard therapy during AMANA (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04750057\">NCT04750057<\/jats:ext-link>\n                      ) or the France Temporary Authorisation for Use (ATUc). The baseline period included \u22656 months of data collection before anifrolumab initiation; follow-up data were collected for as long as data were available in the chart. Outcomes, including SLE Disease Activity Index-2000 (SLEDAI-2K), Physician Global Assessment (PGA) scores and rates of Definition of Remission in SLE (DORIS) and Lupus Low Disease Activity State (LLDAS) attainment, were assessed at baseline and at 6 months from the first anifrolumab dose. Outcome estimation at the 6-month follow-up time point was performed using data from two different windows (primary analysis: 6\u00b11\u2009month; sensitivity analysis: 6\u00b12.5 months).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 47 enrolled patients who initiated anifrolumab, treatment was ongoing in 41 patients (87.2%) at the end of the ERYTHRO study; 6 patients (12.8%) withdrew from anifrolumab (4 (8.5%) due to worsening symptoms, 1 (2.1%) due to improving symptoms and 1 (2.1%) for other reasons). SLEDAI-2K and PGA scores (median (IQR)) decreased over 6 months of treatment (SLEDAI-2K, baseline: 6.0 (8.0), n=47; and 6\u00b11\u2009month: 2.0 (4.0), n=40; PGA, baseline: 1.8 (1.0), n=39; and 6\u00b11\u2009month: 0.3 (1.0), n=29). DORIS remission and LLDAS attainment rates increased from baseline over time (DORIS, baseline: 0\/39; 6\u00b11 month: 9\/29, 31.0%; and LLDAS, baseline: 3\/39, 7.7%; 6\u00b11\u2009month: 17\/29, 58.6%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on the changes in disease activity and attainment of DORIS remission and LLDAS seen within 6 months of anifrolumab initiation, this study supports anifrolumab use in a real-world population of patients with moderate to severe SLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2025-001704","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:50:14Z","timestamp":1776271814000},"page":"e001704","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world experience of anifrolumab treatment in patients with moderate-to-severe SLE: a retrospective study of patients in early access programmes"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct06046534","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04750057","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06046534","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04750057","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02794285","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01753193","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Edward M","family":"Vital","sequence":"first","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2580-8607","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Chasset","sequence":"additional","affiliation":[{"name":"Service de Dermatologie et Allergologie, Facult\u00e9 de m\u00e9decine, Sorbonne University, Tenon Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Faria","sequence":"additional","affiliation":[{"name":"Unidade de Imunologia Cl\u00ednica, Unidade Local de Sa\u00fade de Santo Ant\u00f3nio, Porto, Portugal"},{"name":"Unit for Multidisciplinary Research in Biomedicine, ICBAS School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy M","family":"Carter","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Kielar","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie Y","family":"Chen","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Chen","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonatan","family":"N\u00e5tman","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miina","family":"Waratani","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026072811151570000_13.1.e001704.1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073980","article-title":"Advances in the management of systemic lupus erythematosus","volume":"383","author":"Morand","year":"2023","journal-title":"BMJ"},{"key":"2026072811151570000_13.1.e001704.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2026072811151570000_13.1.e001704.3","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000590","article-title":"Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026072811151570000_13.1.e001704.4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/2229-3485.173779","article-title":"Early access programs: Benefits, challenges, and key considerations for successful implementation","volume":"7","author":"Patil","year":"2016","journal-title":"Perspect Clin Res"},{"key":"2026072811151570000_13.1.e001704.5","first-page":"1254","article-title":"Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus","volume":"30","author":"Furie","year":"2021","journal-title":"Lupus (Los Angel)"},{"key":"2026072811151570000_13.1.e001704.6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026072811151570000_13.1.e001704.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222748"},{"key":"2026072811151570000_13.1.e001704.8","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"The Lancet Rheumatology"},{"key":"2026072811151570000_13.1.e001704.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"2026072811151570000_13.1.e001704.10","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1"},{"key":"2026072811151570000_13.1.e001704.11","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003270","article-title":"Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice","volume":"9","author":"Tanaka","year":"2023","journal-title":"RMD Open"},{"key":"2026072811151570000_13.1.e001704.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.02.044"},{"key":"2026072811151570000_13.1.e001704.13","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1177\/09612033241261746","article-title":"Anifrolumab treatment improves patient-reported quality of life and decreases disease activity and corticosteroid use in patients with systemic lupus erythematosus: A qualitative study in Denmark","volume":"33","author":"Troldborg","year":"2024","journal-title":"Lupus"},{"key":"2026072811151570000_13.1.e001704.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0053"},{"key":"2026072811151570000_13.1.e001704.15","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1093\/rheumatology\/kead568","article-title":"Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry","volume":"63","author":"Miyazaki","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026072811151570000_13.1.e001704.16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/bjd\/ljad089","article-title":"Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers","volume":"189","author":"Carter","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026072811151570000_13.1.e001704.17","unstructured":"Clinigen I , AstraZeneca . Anifrolumab early access program."},{"key":"2026072811151570000_13.1.e001704.18","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/art.41598","article-title":"Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study","volume":"73","author":"Chatham","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026072811151570000_13.1.e001704.19","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026072811151570000_13.1.e001704.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.1418"},{"key":"2026072811151570000_13.1.e001704.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23889.x"},{"key":"2026072811151570000_13.1.e001704.22","doi-asserted-by":"publisher","DOI":"10.1179\/175709208X334614"},{"key":"2026072811151570000_13.1.e001704.23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3111\/13696998.2015.1109518","article-title":"A retrospective study of persistence, adherence and health economic outcomes of fixed-dose combination vs loose-dose combination of oral anti-diabetes drugs","volume":"19","author":"Lokhandwala","year":"2016","journal-title":"J Med Econ"},{"key":"2026072811151570000_13.1.e001704.24","first-page":"1","article-title":"Medication Adherence Measures: An Overview","volume":"2015","author":"Lam","year":"2015","journal-title":"Biomed Res Int"},{"key":"2026072811151570000_13.1.e001704.25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti\u2013interferon","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026072811151570000_13.1.e001704.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"2026072811151570000_13.1.e001704.27","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.40571","article-title":"Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort","volume":"70","author":"Petri","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026072811151570000_13.1.e001704.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224919"},{"key":"2026072811151570000_13.1.e001704.29","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001206","article-title":"Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins Lupus Cohort","volume":"11","author":"Hunnicutt","year":"2024","journal-title":"Lupus Sci Med"},{"key":"2026072811151570000_13.1.e001704.30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.09.004","article-title":"Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study","volume":"86","author":"Iaccarino","year":"2018","journal-title":"J Autoimmun"},{"key":"2026072811151570000_13.1.e001704.31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/rheumatology\/keae120","article-title":"Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up","volume":"64","author":"Parodis","year":"2025","journal-title":"Rheumatology (Oxford)"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:15:28Z","timestamp":1785262528000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,15]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/lupus-2025-001704"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001704","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}